As an Amgen’s PhIII cardio plan takes shape, Royalty Pharma snags a stake in future sales

A few days after Amgen charted a Phase III map for an up-and-coming cardio drug, the biotech behind its development has decided to cash out.

Arrowhead Pharmaceuticals announced Wednesday morning that it has sold its royalty stake in olpasiran, a siRNA drug developed in-house, to Royalty Pharma for $250 million...

Click to view original post